<DOC>
	<DOCNO>NCT01420185</DOCNO>
	<brief_summary>RATIONALE : Studying sample tumor tissue patient cancer laboratory may help doctor identify learn biomarkers related cancer . It may also help doctor predict whether cancer come back treatment . PURPOSE : This research trial study gene may predict local recurrence sample patient breast cancer . treat NSABP-B-28</brief_summary>
	<brief_title>Identification Genes That Predict Local Recurrence Samples From Patients With Breast Cancer Treated NSABP-B-28</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate association 21-gene Recurrence Score risk local-regional recurrence ( LRR ) node-positive , estrogen receptor- ( ER ) positive ( + ) patient treat cyclophosphamide doxorubicin hydrochloride ( AC ) without paclitaxel NSABP-B-28 trial . - To evaluate potential combine 21-gene Recurrence Score ( RS ) traditional clinico-pathologic factor order derive improve algorithm prediction LRR risk order identify subgroup ER-positive patient 1-3 4 positive node do/do need post mastectomy chest wall radiotherapy ( XRT ) regional nodal XRT ( irrespective surgical procedure ) . - To evaluate whether 21-gene RS predict benefit add paclitaxel AC chemotherapy reduce risk LRR , improve disease-free survival ( DFS ) overall survival ( OS ) node-positive , ER-positive patient NSABP-B-28 . OUTLINE : RNA extract paraffin-embedded tissue sample analyze gene expression profile Ribogreen assay RT-PCR . Results compare analyzed patient clinical-pathologic factor , include tumor size , patient age , number positive node ( 1-3 , 4+ ) , tumor grade , surgery type ( mastectomy lumpectomy ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosed breast cancer enrol NSABPB28 . Estrogenreceptor positive ( ER+ ) Nodepositive disease Primary tumor tissue sample available Treated cyclophosphamide doxorubicin hydrochloride tamoxifen without paclitaxel PATIENT CHARACTERISTICS : Menopausal status specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>